CAR T-Cell Therapy Shows Promise for Severe Rheumatoid Arthritis in Small Study
Rheumatoid arthritis is an autoimmune condition in which the immune system mistakenly attacks the joints, causing pain, swelling, and stiffness. For some patients, existing treatments—including immunosuppressants and biologic drugs—provide inadequate relief. A new study explored whether CAR T-cell therapy, which has shown success against certain blood cancers, could help.
Researchers treated six people with severe, refractory rheumatoid arthritis using CAR T cells engineered to target and eliminate B cells, a type of immune cell thought to contribute to autoimmune inflammation. The results were striking: all six patients experienced significant reductions in disease activity, and three reached full remission without the need for ongoing medication.
Scientists believe the therapy works by depleting the harmful B-cell population and effectively resetting part of the immune system. However, the study was very small, and the authors caution that much larger clinical trials are needed before the approach could become a treatment option. Questions about long-term safety, cost, and durability of remission also remain to be answered.
Despite these unknowns, the findings represent an early but encouraging signal that CAR T-cell therapy—originally developed for oncology—may have broader applications in treating autoimmune diseases.